L452R and Y453F SARS-CoV-2 mutations increase transmission and evade immunity

Mutations from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have created multiple variants. Some variants, such as those found

Read more

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

In a methodologically ‘state-of-the-art’ approach, US researchers have developed a protein-based nanoparticle vaccine against coronavirus disease (COVID-19), with a swift

Read more

Dual-action monoclonal antibodies from an original SARS survivor show promise against COVID-19

A recent study, currently available on the bioRxiv* preprint server, indicates that a pair of dual-action monoclonal antibodies derived from

Read more

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

COVID-19 (coronavirus disease 2019) is caused by a new positive-strand RNA coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),

Read more

Study explores individual differences of SARS-CoV-2 infection in ACE2-expressing stem cells

The clinical phenotype of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is remarkable

Read more

Could rotavirus vaccine platforms aid in the immunization campaign against SARS-CoV-2?

Rotavirus is a common diarrheal disease that affects young children. Live oral rotavirus vaccines have been used to reduce its

Read more

A glycan controls how SARS-CoV-2’s spike protein opens, study finds

Using simulations, a team of researchers in the U.S. found that the glycan at position N343 of the severe acute

Read more

Perjeta

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. PERJETA 180903 Contains the active ingredient pertuzumab

Read more